Drug Profile
Cenegermin - Dompe Farmaceutici
Alternative Names: Cenegermin-bkbj; Nerve growth factor - Anabasis/Dompe; Ophtha-NGF; Ophtha-NGF Intravitreal; Oxervate; rhNGF; SentinelLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Anabasis Pharma
- Developer Dompe Farmaceutici; Ospedale San Raffaele
- Class Anti-inflammatories; Antiglaucomas; Eye disorder therapies; Nerve growth factors; Neuroprotectants; Proteins
- Mechanism of Action Nerve growth factor receptor agonists; Neuron stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Keratitis
- Phase III Dry eyes
- Phase II Glaucoma; Retinitis pigmentosa
- Phase I Eye disorders
Most Recent Events
- 22 Jan 2024 Dompe Farmaceutici initiates a phase II trial for Dry eyes in Italy and USA (NCT06244316)
- 13 Mar 2023 Phase-I clinical trials in Eye disorders in Italy (Intravitreous) before 2023 (Dompe-Farmaceutici pipeline, March 2023)
- 09 Feb 2022 Dompé Farmaceutici initiates enrolment in a phase III PROTEGO-2 trial for Dry eye disease (Sjogren's dry eye syndrome), in USA and Italy (Ophthalmic, Drops) (NCT05136170) (EudraCT2021-003749-39)